{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T08:32:08Z","timestamp":1785141128734,"version":"3.55.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1038\/s41401-023-01205-4","type":"journal-article","created":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T08:02:47Z","timestamp":1702972967000},"page":"867-878","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Epigenetic-based combination therapy and liposomal codelivery overcomes osimertinib-resistant NSCLC via repolarizing tumor-associated macrophages"],"prefix":"10.1038","volume":"45","author":[{"given":"Ting-ting","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gui-hua","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin-fu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-lin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-wen","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong-zhuo","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,19]]},"reference":[{"key":"1205_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","volume":"12","author":"W Pao","year":"2011","unstructured":"Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12:175\u201380.","journal-title":"Lancet Oncol"},{"key":"1205_CR2","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1056\/NEJMoa044238","volume":"352","author":"S Kobayashi","year":"2005","unstructured":"Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786\u201392.","journal-title":"N Engl J Med"},{"key":"1205_CR3","doi-asserted-by":"publisher","first-page":"e73","DOI":"10.1371\/journal.pmed.0020073","volume":"2","author":"W Pao","year":"2005","unstructured":"Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73.","journal-title":"PLoS Med"},{"key":"1205_CR4","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.cllc.2017.02.005","volume":"18","author":"J Remon","year":"2017","unstructured":"Remon J, Menis J, Hasan B, Peric A, De Maio E, Novello S, et al. The APPLE trial: feasibility and activity of AZD9291 (Osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. Clin Lung Cancer. 2017;18:583\u20138.","journal-title":"Clin Lung Cancer."},{"key":"1205_CR5","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1177\/1753465816670498","volume":"10","author":"I Sullivan","year":"2016","unstructured":"Sullivan I, Planchard D. Osimertinib in the treatment of patients with epidermal growth factor receptor T790M mutation-positive metastatic non-small cell lung cancer: clinical trial evidence and experience. Ther Adv Respir Dis. 2016;10:549\u201365.","journal-title":"Ther Adv Respir Dis"},{"key":"1205_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJMoa1913662","volume":"382","author":"SS Ramalingam","year":"2020","unstructured":"Ramalingam SS, Vansteenkiste J, Planchard D, Cho BC, Gray JE, Ohe Y, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med. 2020;382:41\u201350.","journal-title":"N Engl J Med."},{"key":"1205_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1038\/nature17960","volume":"534","author":"Y Jia","year":"2016","unstructured":"Jia Y, Yun CH, Park E, Ercan D, Manuia M, Juarez J, et al. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016;534:129\u201332.","journal-title":"Nature"},{"key":"1205_CR8","doi-asserted-by":"crossref","unstructured":"He J, Huang Z, Han L, Gong Y, Xie C. Mechanisms and management of 3rd generation EGFRTKI resistance in advanced nonsmall cell lung cancer (Review). Int J Oncol. 2021;59:90.","DOI":"10.3892\/ijo.2021.5270"},{"key":"1205_CR9","doi-asserted-by":"publisher","first-page":"1209947","DOI":"10.3389\/fimmu.2023.1209947","volume":"14","author":"D Cheng","year":"2023","unstructured":"Cheng D, Ge K, Yao X, Wang B, Chen R, Zhao W, et al. Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects. Front Immunol. 2023;14:1209947.","journal-title":"Front Immunol"},{"key":"1205_CR10","doi-asserted-by":"crossref","unstructured":"Erin N, Grahovac J, Brozovic A, Efferth T. Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance. Drug Resist Updat. 2020;53:100715.","DOI":"10.1016\/j.drup.2020.100715"},{"key":"1205_CR11","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1038\/nrclinonc.2017.44","volume":"14","author":"T Shibue","year":"2017","unstructured":"Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14:611\u201329.","journal-title":"Nat Rev Clin Oncol"},{"key":"1205_CR12","doi-asserted-by":"publisher","first-page":"172","DOI":"10.21037\/tlcr.2016.04.07","volume":"5","author":"KR Jakobsen","year":"2016","unstructured":"Jakobsen KR, Demuth C, Sorensen BS, Nielsen AL. The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Transl Lung Cancer Res. 2016;5:172\u201382.","journal-title":"Transl Lung Cancer Res"},{"key":"1205_CR13","doi-asserted-by":"publisher","first-page":"7291","DOI":"10.7150\/jca.46429","volume":"11","author":"L Chen","year":"2020","unstructured":"Chen L, Lin G, Chen K, Liang R, Wan F, Zhang C, et al. VEGF promotes migration and invasion by regulating EMT and MMPs in nasopharyngeal carcinoma. J Cancer. 2020;11:7291\u2013301.","journal-title":"J Cancer"},{"key":"1205_CR14","doi-asserted-by":"publisher","first-page":"104119","DOI":"10.1016\/j.cellimm.2020.104119","volume":"353","author":"LQ Fu","year":"2020","unstructured":"Fu LQ, Du WL, Cai MH, Yao JY, Zhao YY, Mou XZ. The roles of tumor-associated macrophages in tumor angiogenesis and metastasis. Cell Immunol. 2020;353:104119.","journal-title":"Cell Immunol"},{"key":"1205_CR15","doi-asserted-by":"crossref","unstructured":"Osude C, Lin L, Patel M, Eckburg A, Berei J, Kuckovic A, et al. Mediating EGFR-TKI resistance by VEGF\/VEGFR autocrine pathway in non-small cell lung cancer. Cells. 2022;11:1694.","DOI":"10.3390\/cells11101694"},{"key":"1205_CR16","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.yexcr.2009.11.020","volume":"316","author":"O Gonzalez-Moreno","year":"2010","unstructured":"Gonzalez-Moreno O, Lecanda J, Green JE, Segura V, Catena R, Serrano D, et al. VEGF elicits epithelial-mesenchymal transition (EMT) in prostate intraepithelial neoplasia (PIN)-like cells via an autocrine loop. Exp Cell Res. 2010;316:554\u201367.","journal-title":"Exp Cell Res"},{"key":"1205_CR17","doi-asserted-by":"publisher","first-page":"836223","DOI":"10.3389\/fimmu.2022.836223","volume":"13","author":"Y Niu","year":"2022","unstructured":"Niu Y, Chen J, Qiao Y. Epigenetic modifications in tumor-associated macrophages: a new perspective for an old foe. Front Immunol. 2022;13:836223.","journal-title":"Front Immunol"},{"key":"1205_CR18","doi-asserted-by":"publisher","first-page":"109955","DOI":"10.1016\/j.celrep.2021.109955","volume":"37","author":"L He","year":"2021","unstructured":"He L, Jhong JH, Chen Q, Huang KY, Strittmatter K, Kreuzer J, et al. Global characterization of macrophage polarization mechanisms and identification of M2-type polarization inhibitors. Cell Rep. 2021;37:109955.","journal-title":"Cell Rep"},{"key":"1205_CR19","doi-asserted-by":"publisher","first-page":"3359","DOI":"10.1038\/onc.2016.485","volume":"36","author":"CC Wong","year":"2017","unstructured":"Wong CC, Qian Y, Yu J. Interplay between epigenetics and metabolism in oncogenesis: mechanisms and therapeutic approaches. Oncogene. 2017;36:3359\u201374.","journal-title":"Oncogene"},{"key":"1205_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.cmet.2018.08.006","volume":"28","author":"M Apicella","year":"2018","unstructured":"Apicella M, Giannoni E, Fiore S, Ferrari KJ, Fernandez-Perez D, Isella C, et al. Increased lactate secretion by cancer cells sustains non-cell-autonomous adaptive resistance to MET and EGFR targeted therapies. Cell Metab. 2018;28:848\u201365. e6.","journal-title":"Cell Metab"},{"key":"1205_CR21","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1016\/j.apsb.2021.09.022","volume":"12","author":"Y He","year":"2022","unstructured":"He Y, Fang Y, Zhang M, Zhao Y, Tu B, Shi M, et al. Remodeling \u201ccold\u201d tumor immune microenvironment via epigenetic-based therapy using targeted liposomes with in situ formed albumin corona. Acta Pharm Sin B. 2022;12:2057\u201373.","journal-title":"Acta Pharm Sin B"},{"key":"1205_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-015-1967-5","volume":"15","author":"G Greve","year":"2015","unstructured":"Greve G, Schiffmann I, Pfeifer D, Pantic M, Schuler J, Lubbert M. The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells. BMC Cancer. 2015;15:947.","journal-title":"BMC Cancer"},{"key":"1205_CR23","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1002\/ijc.30888","volume":"141","author":"WY Lee","year":"2017","unstructured":"Lee WY, Chen PC, Wu WS, Wu HC, Lan CH, Huang YH, et al. Panobinostat sensitizes KRAS-mutant non-small-cell lung cancer to gefitinib by targeting TAZ. Int J Cancer. 2017;141:1921\u201331.","journal-title":"Int J Cancer"},{"key":"1205_CR24","doi-asserted-by":"publisher","first-page":"2935","DOI":"10.1021\/acs.nanolett.9b00021","volume":"19","author":"H Wang","year":"2019","unstructured":"Wang H, Tang Y, Fang Y, Zhang M, Wang H, He Z, et al. Reprogramming tumor immune microenvironment (TIME) and metabolism via biomimetic targeting codelivery of shikonin\/JQ1. Nano Lett. 2019;19:2935\u201344.","journal-title":"Nano Lett"},{"key":"1205_CR25","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jconrel.2020.10.052","volume":"329","author":"P Zhao","year":"2021","unstructured":"Zhao P, Zhang J, Wu A, Zhang M, Zhao Y, Tang Y, et al. Biomimetic codelivery overcomes osimertinib-resistant NSCLC and brain metastasis via macrophage-mediated innate immunity. J Control Release. 2021;329:1249\u201361.","journal-title":"J Control Release"},{"key":"1205_CR26","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.3389\/fimmu.2019.02215","volume":"10","author":"K Kielbassa","year":"2019","unstructured":"Kielbassa K, Vegna S, Ramirez C, Akkari L. Understanding the origin and diversity of macrophages to tailor their targeting in solid cancers. Front Immunol. 2019;10:2215.","journal-title":"Front Immunol"},{"key":"1205_CR27","doi-asserted-by":"publisher","first-page":"265","DOI":"10.7150\/thno.27246","volume":"9","author":"H Jin","year":"2019","unstructured":"Jin H, He Y, Zhao P, Hu Y, Tao J, Chen J, et al. Targeting lipid metabolism to overcome EMT-associated drug resistance via integrin beta3\/FAK pathway and tumor-associated macrophage repolarization using legumain-activatable delivery. Theranostics. 2019;9:265\u201378.","journal-title":"Theranostics"},{"key":"1205_CR28","doi-asserted-by":"publisher","first-page":"e1802372","DOI":"10.1002\/smll.201802372","volume":"14","author":"W Yin","year":"2018","unstructured":"Yin W, Yu X, Kang X, Zhao Y, Zhao P, Jin H, et al. Remodeling tumor-associated macrophages and neovascularization overcomes EGFR(T790M) -associated drug resistance by PD-L1 nanobody-mediated codelivery. Small. 2018;14:e1802372.","journal-title":"Small"},{"key":"1205_CR29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-21-3503","volume":"82","author":"C Chen","year":"2022","unstructured":"Chen C, Man N, Liu F, Martin GM, Itonaga H, Sun J, et al. Epigenetic and transcriptional regulation of innate immunity in cancer. Cancer Res. 2022;82:2047\u201356.","journal-title":"Cancer Res"},{"key":"1205_CR30","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/s41388-020-01636-x","volume":"40","author":"X Li","year":"2021","unstructured":"Li X, Su X, Liu R, Pan Y, Fang J, Cao L, et al. HDAC inhibition potentiates anti-tumor activity of macrophages and enhances anti-PD-L1-mediated tumor suppression. Oncogene. 2021;40:1836\u201350.","journal-title":"Oncogene"},{"key":"1205_CR31","doi-asserted-by":"publisher","first-page":"7684","DOI":"10.1021\/acs.nanolett.7b03756","volume":"17","author":"H Peng","year":"2017","unstructured":"Peng H, Chen B, Huang W, Tang Y, Jiang Y, Zhang W, et al. Reprogramming tumor-associated macrophages to reverse EGFR(T790M) resistance by dual-targeting codelivery of gefitinib\/vorinostat. Nano Lett. 2017;17:7684\u201390.","journal-title":"Nano Lett"},{"key":"1205_CR32","doi-asserted-by":"publisher","first-page":"e8458","DOI":"10.7717\/peerj.8458","volume":"8","author":"D Sun","year":"2020","unstructured":"Sun D, Luo T, Dong P, Zhang N, Chen J, Zhang S, et al. CD86+\/CD206+ tumor-associated macrophages predict prognosis of patients with intrahepatic cholangiocarcinoma. PeerJ. 2020;8:e8458.","journal-title":"PeerJ"},{"key":"1205_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/nrc3819","volume":"14","author":"R Brown","year":"2014","unstructured":"Brown R, Curry E, Magnani L, Wilhelm-Benartzi CS, Borley J. Poised epigenetic states and acquired drug resistance in cancer. Nat Rev Cancer. 2014;14:747\u201353.","journal-title":"Nat Rev Cancer"},{"key":"1205_CR34","doi-asserted-by":"publisher","first-page":"113825","DOI":"10.1016\/j.ejmech.2021.113825","volume":"226","author":"M Zhou","year":"2021","unstructured":"Zhou M, Yuan M, Zhang M, Lei C, Aras O, Zhang X, et al. Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy. Eur J Med Chem. 2021;226:113825.","journal-title":"Eur J Med Chem"},{"key":"1205_CR35","doi-asserted-by":"publisher","first-page":"582370","DOI":"10.3389\/fcell.2020.582370","volume":"8","author":"H Mamdani","year":"2020","unstructured":"Mamdani H, Jalal SI. Histone deacetylase inhibition in non-small cell lung cancer: hype or hope? Front Cell Dev Biol. 2020;8:582370.","journal-title":"Front Cell Dev Biol"},{"key":"1205_CR36","doi-asserted-by":"publisher","first-page":"7166","DOI":"10.1039\/D0BM01516D","volume":"8","author":"B Tu","year":"2020","unstructured":"Tu B, He Y, Chen B, Wang Y, Gao Y, Shi M, et al. Deformable liposomal codelivery of vorinostat and simvastatin promotes antitumor responses through remodeling tumor microenvironment. Biomater Sci. 2020;8:7166\u201376.","journal-title":"Biomater Sci"},{"key":"1205_CR37","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","volume":"9","author":"KG de la Cruz-Lopez","year":"2019","unstructured":"de la Cruz-Lopez KG, Castro-Munoz LJ, Reyes-Hernandez DO, Garcia-Carranca A, Manzo-Merino J. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. 2019;9:1143.","journal-title":"Front Oncol"},{"key":"1205_CR38","doi-asserted-by":"publisher","first-page":"103627","DOI":"10.1016\/j.ebiom.2021.103627","volume":"73","author":"ZH Wang","year":"2021","unstructured":"Wang ZH, Peng WB, Zhang P, Yang XP, Zhou Q. Lactate in the tumour microenvironment: From immune modulation to therapy. EBioMedicine. 2021;73:103627.","journal-title":"EBioMedicine"},{"key":"1205_CR39","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1016\/j.humimm.2022.02.007","volume":"83","author":"KK Goswami","year":"2022","unstructured":"Goswami KK, Banerjee S, Bose A, Baral R. Lactic acid in alternative polarization and function of macrophages in tumor microenvironment. Hum Immunol. 2022;83:409\u201317.","journal-title":"Hum Immunol"},{"key":"1205_CR40","doi-asserted-by":"publisher","first-page":"6122","DOI":"10.7150\/thno.42234","volume":"10","author":"W Yin","year":"2020","unstructured":"Yin W, Zhao Y, Kang X, Zhao P, Fu X, Mo X, et al. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR(T790M) mutation. Theranostics. 2020;10:6122\u201335.","journal-title":"Theranostics"},{"key":"1205_CR41","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","volume":"20","author":"C Viallard","year":"2017","unstructured":"Viallard C, Larrivee B. Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017;20:409\u201326.","journal-title":"Angiogenesis"},{"key":"1205_CR42","first-page":"3395","volume":"42","author":"Z Liu","year":"2018","unstructured":"Liu Z, Kuang W, Zhou Q, Zhang Y. TGF-beta1 secreted by M2 phenotype macrophages enhances the stemness and migration of glioma cells via the SMAD2\/3 signalling pathway. Int J Mol Med. 2018;42:3395\u2013403.","journal-title":"Int J Mol Med"},{"key":"1205_CR43","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.canlet.2019.03.015","volume":"452","author":"S Wang","year":"2019","unstructured":"Wang S, Liu R, Yu Q, Dong L, Bi Y, Liu G. Metabolic reprogramming of macrophages during infections and cancer. Cancer Lett. 2019;452:14\u201322.","journal-title":"Cancer Lett"},{"key":"1205_CR44","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1038\/s41416-019-0573-8","volume":"121","author":"A Leonetti","year":"2019","unstructured":"Leonetti A, Sharma S, Minari R, Perego P, Giovannetti E, Tiseo M. Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer. Br J Cancer. 2019;121:725\u201337.","journal-title":"Br J Cancer"},{"key":"1205_CR45","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1056\/NEJMoa1612674","volume":"376","author":"TS Mok","year":"2017","unstructured":"Mok TS, Wu YL, Ahn MJ, Garassino MC, Kim HR, Ramalingam SS, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-positive lung cancer. N Engl J Med. 2017;376:629\u201340.","journal-title":"N Engl J Med"},{"key":"1205_CR46","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.lungcan.2020.07.014","volume":"147","author":"S Schmid","year":"2020","unstructured":"Schmid S, Li JJN, Leighl NB. Mechanisms of osimertinib resistance and emerging treatment options. Lung Cancer. 2020;147:123\u20139.","journal-title":"Lung Cancer"},{"key":"1205_CR47","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.21037\/tlcr-21-572","volume":"10","author":"L Liu","year":"2021","unstructured":"Liu L, Wang C, Li S, Bai H, Wang J. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review. Transl Lung Cancer Res. 2021;10:3823\u201339.","journal-title":"Transl Lung Cancer Res"},{"key":"1205_CR48","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-014-0127-0","volume":"31","author":"B Zhang","year":"2014","unstructured":"Zhang B, Zhang Y, Zhao J, Wang Z, Wu T, Ou W, et al. M2-polarized macrophages contribute to the decreased sensitivity of EGFR-TKIs treatment in patients with advanced lung adenocarcinoma. Med Oncol. 2014;31:127.","journal-title":"Med Oncol"},{"key":"1205_CR49","doi-asserted-by":"publisher","first-page":"E227","DOI":"10.1002\/ijc.27403","volume":"131","author":"FT Chung","year":"2012","unstructured":"Chung FT, Lee KY, Wang CW, Heh CC, Chan YF, Chen HW, et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer. 2012;131:E227\u201335.","journal-title":"Int J Cancer"},{"key":"1205_CR50","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1080\/08830185.2021.1955876","volume":"41","author":"HC Zhou","year":"2022","unstructured":"Zhou HC, Xin-Yan Y, Yu WW, Liang XQ, Du XY, Liu ZC, et al. Lactic acid in macrophage polarization: The significant role in inflammation and cancer. Int Rev Immunol. 2022;41:4\u201318.","journal-title":"Int Rev Immunol"},{"key":"1205_CR51","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.cell.2014.07.032","volume":"158","author":"YD Shaul","year":"2014","unstructured":"Shaul YD, Freinkman E, Comb WC, Cantor JR, Tam WL, Thiru P, et al. Dihydropyrimidine accumulation is required for the epithelial-mesenchymal transition. Cell. 2014;158:1094\u2013109.","journal-title":"Cell"},{"key":"1205_CR52","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1182\/blood-2006-07-035972","volume":"109","author":"K Fischer","year":"2007","unstructured":"Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M, et al. Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007;109:3812\u20139.","journal-title":"Blood"},{"key":"1205_CR53","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/1878-0261.12162","volume":"12","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Ma J, Fan Y, Wang Z, Tian R, Ji W, et al. TGF-\u03b2 transactivates EGFR and facilitates breast cancer migration and invasion through canonical Smad3 and ERK\/Sp1 signaling pathways. Mol Oncol. 2018;12:305\u201321.","journal-title":"Mol Oncol"},{"key":"1205_CR54","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.cell.2012.07.018","volume":"150","author":"W Yang","year":"2012","unstructured":"Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, et al. PKM2 phosphorylates histone H3 and promotes gene transcription and tumorigenesis. Cell. 2012;150:685\u201396.","journal-title":"Cell"},{"key":"1205_CR55","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/nature10598","volume":"480","author":"W Yang","year":"2011","unstructured":"Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, et al. Nuclear PKM2 regulates beta-catenin transactivation upon EGFR activation. Nature. 2011;480:118\u201322.","journal-title":"Nature"},{"key":"1205_CR56","doi-asserted-by":"publisher","first-page":"15526","DOI":"10.1073\/pnas.1407717111","volume":"111","author":"A Hamabe","year":"2014","unstructured":"Hamabe A, Konno M, Tanuma N, Shima H, Tsunekuni K, Kawamoto K, et al. Role of pyruvate kinase M2 in transcriptional regulation leading to epithelial-mesenchymal transition. Proc Natl Acad Sci USA. 2014;111:15526\u201331.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1205_CR57","doi-asserted-by":"crossref","unstructured":"Long L, Xiong W, Lin F, Hou J, Chen G, Peng T, et al. Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery. J Exp Clin Cancer Res. 2023;42:117.","DOI":"10.1186\/s13046-023-02688-z"},{"key":"1205_CR58","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-14-4","volume":"14","author":"C Fischer","year":"2015","unstructured":"Fischer C, Leithner K, Wohlkoenig C, Quehenberger F, Bertsch A, Olschewski A, et al. Panobinostat reduces hypoxia-induced cisplatin resistance of non-small cell lung carcinoma cells via HIF-1alpha destabilization. Mol Cancer. 2015;14:4.","journal-title":"Mol Cancer"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01205-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01205-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,15]],"date-time":"2024-03-15T12:03:23Z","timestamp":1710504203000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-023-01205-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,19]]},"references-count":58,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["1205"],"URL":"https:\/\/doi.org\/10.1038\/s41401-023-01205-4","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,19]]},"assertion":[{"value":"22 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}